Cargando…

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression

SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common hematological neoplasia with a high incidence in elderly populations. The disease is characterized by a severe chaos of genomic abnormality. Comprehensive examinations of myeloma cytogenetics are needed for better understanding of MM an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Can, Wendlandt, Erik B., Darbro, Benjamin, Xu, Hongwei, Thomas, Gregory S., Tricot, Guido, Chen, Fangping, Shaughnessy, John D., Zhan, Fenghuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866300/ https://www.ncbi.nlm.nih.gov/pubmed/33572851 http://dx.doi.org/10.3390/cancers13030517

Ejemplares similares

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
por: Gu, Zhimin, et al.
Publicado: (2014)

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
por: Roy Choudhury, Samrat, et al.
Publicado: (2023)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
por: Shi, Lei, et al.
Publicado: (2010)

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
por: Han, Seong-Su, et al.
Publicado: (2015)

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
por: Zhao, Duoduo, et al.
Publicado: (2023)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
por: Guo, Wancheng, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression
por: Dib, Amel, et al.
Publicado: (2006)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Interpretation of cytogenetic results in multiple myeloma for clinical practice
por: Rajan, A M, et al.
Publicado: (2015)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma
por: Smol, Thomas, et al.
Publicado: (2017)

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients
por: Roy Choudhury, Samrat, et al.
Publicado: (2021)

Conventional and Molecular Cytogenetic Analyses in Turkish Patients with Multiple Myeloma
por: Durak, Beyhan Aras, et al.
Publicado: (2012)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma
por: Yang, Naery, et al.
Publicado: (2018)

Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
por: Brenne, Anne-Tove, et al.
Publicado: (2009)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression
por: Zhang, Zijun, et al.
Publicado: (2023)

The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ Hybridization and Their Potential Diagnostic Utility
por: Lim, Chang-Sup, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btrrpdgvfbp9kk3nspm6gf1276